v3.24.1.u1
Segment Information (Tables)
 3 Months Ended
Mar. 31, 2024
Segment Reporting [Abstract]  
Schedule of worldwide net revenues
The following table details AbbVie’s worldwide net revenues:
Three months ended
March 31,
(in millions)20242023
Immunology
HumiraUnited States$1,771 $2,948 
International499 593 
Total$2,270 $3,541 
SkyriziUnited States$1,656 $1,139 
International352 221 
Total$2,008 $1,360 
RinvoqUnited States$725 $449 
International368 237 
Total$1,093 $686 
Oncology
ImbruvicaUnited States$610 $638 
Collaboration revenues228 240 
Total$838 $878 
VenclextaUnited States$281 $265 
International333 273 
Total$614 $538 
Elahere(a)
United States
$64 $— 
EpkinlyCollaboration Revenues$22 $— 
International5 — 
Total$27 $— 
Aesthetics
Botox CosmeticUnited States$389 $409 
International244 250 
Total$633 $659 
Juvederm CollectionUnited States$106 $122 
International191 233 
Total$297 $355 
Other AestheticsUnited States$281 $246 
International38 40 
Total$319 $286 
Neuroscience
Botox TherapeuticUnited States$611 $587 
International137 132 
Total$748 $719 
VraylarUnited States$692 $560 
International2 1 
Total$694 $561 
Three months ended
March 31,
(in millions)20242023
DuodopaUnited States$25 $25 
International90 93 
Total$115 $118 
UbrelvyUnited States$197 $150 
International6 2 
Total$203 $152 
QuliptaUnited States$128 $66 
International3 — 
Total$131 $66 
Other NeuroscienceUnited States$61 $75 
International13 4 
Total$74 $79 
Eye Care
OzurdexUnited States$34 $39 
International97 76 
Total131 115 
Lumigan/GanfortUnited States$29 $63 
International62 67 
Total$91 $130 
Alphagan/CombiganUnited States$15 $28 
International44 43 
Total$59 $71 
RestasisUnited States$44 $79 
International13 13 
Total$57 $92 
Other Eye CareUnited States$105 $110 
International95 90 
Total$200 $200 
Other Key Products
MavyretUnited States$144 $171 
International205 193 
Total$349 $364 
CreonUnited States$285 $305 
Linzess/ConstellaUnited States$257 $251 
International9 8 
Total$266 $259 
All other$744 $691 
Total net revenues$12,310 $12,225 
(a)Net revenues include ImmunoGen product revenues after the acquisition closing date of February 12, 2024.